Premium
O2‐08‐05: Neuronal Injury and Degeneration Evaluated with Imaging and CSF Biomarkers in Autosomal Dominant Alzheimer's Disease: Results from the Dian Study
Author(s) -
Joseph-Mathurin Nelly,
Vlassenko Andrei G.,
Fagan Anne M.,
Su Yi,
Friedrichsen Karl A.,
Owen Christopher J.,
Gordon Brian A.,
Hornbeck Russ C.,
Koeppe Robert A.,
Xiong Chengjie,
Morris John C.,
Bateman Randall,
Benzinger Tammie LS.
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.440
Subject(s) - pittsburgh compound b , neurodegeneration , dementia , neuroimaging , medicine , cognitive decline , biomarker , pathology , cerebrospinal fluid , clinical dementia rating , fluorodeoxyglucose , standardized uptake value , positron emission tomography , oncology , disease , nuclear medicine , biology , psychiatry , genetics
plete work-ups were differently represented for the two diagnoses. No statistically significant change emerged in diagnosis, diagnostic confidence or clinical management between complete, intermediate or incomplete assessments (Table). Stratifying patients for etiopathology (AD-FTD) or clinical severity (MCI-dementia) led to the same results. Conclusions:Collection of additional core bio-markers does not seem to affect the incremental value of amyloid-PET in naturalistic clinical setting. The clinicians combinations and use of instrumental examination needs to be better understood and elucidated in view of the definition of an evidence-based diagnostic algorithm.